Equities analysts predict that Heska Corp (NASDAQ:HSKA) will post earnings of ($0.25) per share for the current quarter, according to Zacks. Two analysts have made estimates for Heska’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.32). Heska reported earnings of ($0.03) per share in the same quarter last year, which indicates a negative year over year growth rate of 733.3%. The business is expected to announce its next quarterly earnings report before the market opens on Tuesday, August 4th.
On average, analysts expect that Heska will report full year earnings of ($0.28) per share for the current financial year, with EPS estimates ranging from ($0.44) to ($0.12). For the next fiscal year, analysts anticipate that the business will post earnings of $0.49 per share, with EPS estimates ranging from $0.27 to $0.71. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Heska.
Heska (NASDAQ:HSKA) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.44). Heska had a negative net margin of 5.99% and a negative return on equity of 1.04%. The company had revenue of $30.65 million for the quarter, compared to the consensus estimate of $33.47 million.
HSKA has been the topic of several analyst reports. Zacks Investment Research cut Heska from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. Alliance Global Partners upped their price target on Heska from $78.00 to $90.00 in a research report on Friday, May 8th. BidaskClub upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Piper Sandler decreased their price objective on shares of Heska from $107.00 to $87.00 in a research report on Monday, May 25th. Finally, ValuEngine cut shares of Heska from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Six research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Heska presently has a consensus rating of “Hold” and an average target price of $81.67.
Shares of HSKA opened at $96.22 on Friday. The business’s 50-day moving average price is $92.22 and its 200-day moving average price is $85.11. Heska has a twelve month low of $50.00 and a twelve month high of $110.90. The stock has a market cap of $903.69 million, a PE ratio of -96.22 and a beta of 1.72. The company has a quick ratio of 9.89, a current ratio of 11.21 and a debt-to-equity ratio of 0.19.
In other Heska news, CEO Kevin S. Wilson sold 3,266 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $85.00, for a total value of $277,610.00. Following the completion of the sale, the chief executive officer now owns 104,955 shares of the company’s stock, valued at $8,921,175. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin S. Wilson sold 1,734 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $85.00, for a total value of $147,390.00. Following the completion of the sale, the chief executive officer now directly owns 108,221 shares of the company’s stock, valued at approximately $9,198,785. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,941 shares of company stock valued at $2,741,842. 11.70% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Fred Alger Management LLC boosted its stake in Heska by 3.5% in the first quarter. Fred Alger Management LLC now owns 1,079,219 shares of the medical research company’s stock worth $59,681,000 after buying an additional 36,907 shares in the last quarter. FMR LLC boosted its stake in Heska by 2.0% in the first quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock worth $38,616,000 after buying an additional 8,870 shares in the last quarter. Nine Ten Capital Management LLC boosted its stake in Heska by 1.2% in the first quarter. Nine Ten Capital Management LLC now owns 338,862 shares of the medical research company’s stock worth $18,739,000 after buying an additional 4,178 shares in the last quarter. State Street Corp boosted its stake in Heska by 1.2% in the first quarter. State Street Corp now owns 287,309 shares of the medical research company’s stock worth $15,888,000 after buying an additional 3,430 shares in the last quarter. Finally, Grandeur Peak Global Advisors LLC boosted its stake in shares of Heska by 89.9% during the first quarter. Grandeur Peak Global Advisors LLC now owns 138,756 shares of the medical research company’s stock valued at $7,673,000 after purchasing an additional 65,700 shares during the period. 79.67% of the stock is owned by institutional investors and hedge funds.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Featured Story: What is the Nikkei 225 index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.